

# Duke Debates: Controversies in the Management of Patients with Hematologic Malignancies

**NOW VIRTUAL MEETING!!**

## Friday August 14, 2020

- 7:00-8:15am**            **Vendor site open**
- 8:00-8:05 am**            **Introductions - David Rizzieri, MD**
- 8:05-8:15**                **Pre – conference questionnaire**
- 8:15-9:00 am            **Debate:** All Patients Over the Age of 60 with AML Should Have Induction Therapy with Targeted Agents -(Ven/HMA; Glasdegib/HMA; or similar approach) Rather Than Standard 7 plus 3!  
*PRO: Daniel DeAngelo, MD, PhD (DFCI) vs. CON: Ronan Swords, MD (AbbVie)*
- 9:00-9:45 am            **Debate:** PV Patients Can be Adequately Managed Through the Entire Course of Their Disease With Aspirin, Phlebotomy, Hydroxyurea and/or Interferon  
*PRO: Lindsay Rein, MD vs. CON: Josef Prchal, MD (Utah)*
- 9:45-10:25am            **Debate:** AYA Patients with BCR/ABL Negative ALL Should Receive a Pediatric Inspired Regimen and Reserve allo HSCT for Management of Relapse  
*Wendy Stock, MD (U. Chicago) vs. Anjali Advani, MD (Cleveland Clinic)*
- 10:25-11:05 am            **Product Theater #1**
- 11:05-11:45 am            **Debate:** Radiation Therapy Alone is the Preferred Management for Stage 1 Mantle Cell Lymphoma  
*PRO: Christopher Kelsey, MD vs. CON: Jonathon Cohen, MD, MS (Emory)*
- 11:45am - 12:30 pm            **Debate:** Venetoclax should be used frontline in CLL before Ibrutinib  
*PRO: John Pagel, MD, PhD (SCI) vs. CON: Andrea Sitlinger, MD*
- 12:30-1:10 pm            **Product Theater #2**
- 1:10- 1:50 pm            **Debate:** Patients with relapsed mantle cell lymphoma should receive CAR-T therapy rather than traditional re-induction therapy and transplantation  
*Pro: Jie Wang, MD      Con: David Rizzieri, MD*
- 1:50- 2:20 pm            CAR-T and Immune Therapies Management of Acute and Late Toxicities - What the community provider needs to know  
*Ahmed Galal, MD*
- 2:20-3:00 pm            **Product Theater #3**
- 3:00-3:40 pm            The Role of Molecular Tumor Board in Heme Malignancies and How Duke can support you!  
*Matthew McKinney, MD*
- 3:40-4:20 pm            **Debate:** Sickle Cell Topic: “Novel/New Therapies Are Worth It!”  
*John J. Strouse, MD, PhD vs. Nirmish Shah, MD*
- 4:20 pm                    *Post Test Questions*
- 4:45 pm                    *Conference Evals and MOC directions*
- 4:45 - 5:15pm            **Vendor Site Open**